Open access
Oct 2026
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis
Key Points Question What is the long-term safety and efficacy profile of ocrelizumab in patients with relapsing multiple sclerosis (RMS)? Findings In the OPERA I/II randomized clinical trials including 1656 patients with RMS, treatment with ocrelizumab for up to 10 years led to near-complete and sustained suppression o...
Stephen L. Hauser, Amit Bar-Or, G. Giovannoni et al.
· JAMA Neurology · 0 citations